Last updated: March 20, 2024
Sponsor: A.O.U. Città della Salute e della Scienza
Overall Status: Active - Recruiting
Phase
3
Condition
N/ATreatment
Placebo
Bentelan
Clinical Study ID
NCT06299813
771.284
2022-002955-20
Ages 6-6 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Body Temperature measured with an axillary or ear thermometer >= n 37.5°C, persistingfor a minimum of 6 hours and a maximum of 5 days.
- Clinical presentation consistent with pharyngo-tonsillar infection by Adenovirus,including At least one of the following symptoms: pharyngodonidae /asthenia/nausea/vomiting/diarrhea/cough/rhinorrhea/abdominal pain/otalgia and atleast one of the following signs: pharyngeal hyperemia with or withoutpharyngo-tonsillar exudate/inflammation of the upper or lowerairways/lymphadenopathy/skin rash.-
- Positive result on the antigen test for Adenovirus performed with the "Biosensor"rapid swab.
- Negative result on the swab for Group A Streptococcus (SBEGA), if deemed necessaryfollowing McIsaac criteria
- Informed consent form for participation in the study signed by the parent(s) or legalguardian.
Exclusion
Exclusion Criteria:
- Adequate dosage of betamethasone in the 48 hours prior.
- Underlying chronic illness associated with an increased risk of unusual or severeadenoviral infection.
- Inability to tolerate oral medications.
- Documented allergy or any other known contraindication to Bentelan 0.5mg®medication.-Patients on chronic therapy with anticholinesterases, salicylates,nonsteroidal anti-inflammatory drugs, thiazides, furosemide, amphotericin, xanthines (theophylline), antidiabetic drugs, insulin, cyclosporine, ritonavir, ketoconazole,acetylsalicylic acid, phenytoin, phenobarbital, ephedrine, rifampicin, anticoagulants.
- Subacute or chronic conditions requiring a higher equivalent dose of betamethasone orknown primary or secondary adrenal insufficiency.
- Transfer to another hospital for any reason.
- Parents who are unable to understand the proposed study or cannot reliably participatein phone follow-up due to significant language barriers.
- Participation in another study involving an experimental drug within the 30 days priorto and during the current study.
Study Design
Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
March 20, 2024
Estimated Completion Date:
April 01, 2026
Study Description
Connect with a study center
Ospedale Infantile Regina Margherita
Torino, 10126
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.